Female Fertility Drugs Market: By Drug Type,, By Distribution Mode, By Route of Administration, By Distribution Channel and Region Forecast 2019-2030
Female Fertility Drugs Market size was valued at US$ 3.48 billion in 2023 and is expected to reach US$ 5.35 billion in 2030, at a CAGR of 6.3% from 2024-2030. Female fertility drugs are the agents used to improve reproductive health in women and act to stimulate the follicle development of the ovary. Women's fertility drugs are extremely effective and the first treatment option to overcome infertility. Fertility drugs act by direct stimulation of ovaries or balancing the hormone levels. Infertility in women occurs due to hypothalamic dysfunction, excessive prolactin, pelvic inflammatory diseases, premature ovarian insufficiency, and polycystic ovary syndrome among others. The major symptom associated with infertility is an absence or irregular menstrual cycle. The market is growing at a significant CAGR with several local and international players operating in infertility treatment.
The prevalence of infertility is increasing due to changes in lifestyles such as smoking and alcohol consumption. According to World Health Organization, approximately 60-80 Mn couples are suffering from infertility around the world. Moreover, acquisitions & mergers, collaborations, product approvals, and product launchings are the strategies followed by the companies for increasing their market revenue share in the market. For instance, in March 2014, Ferring Pharmaceuticals received FDA approval for the combination of Menopur and Bravelle injection used in the treatment of infertility.
Study Period
2025-2031Base Year
2024CAGR
6.3%Largest Market
North-AmericaFastest Growing Market
Europe
Increase in the female population, rise in prevalence of infertility condition due to change in lifestyle, government initiation for the infertility management, rise in disposable income are anticipated to fuel the women fertility drugs market over the forecast period. Moreover, increase in R&D activities for the development of new drugs to overcome the infertility, rise in the prevalence of obesity, and increase in the maternal age are expected to boost the women fertility drugs market. However, stringent regulatory policies for drug approvals, lack of awareness about women fertility drugs in underdeveloped countries, and alternative infertility treatments such as in vitro fertilization are expected to restrain the growth of women fertility drugs market over the forecast period.
Geographically, female fertility drugs market is segmented into the North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America driven by increase in the prevalence of female infertility rate due to obesity and lifestyle changes, increase in the R&D activities for the innovation of newer drugs, and rise in awareness about the fertility drugs among the key stakeholders in the region. Europe exhibiting significant growth rate owing to accessibility of the products, increase in the infertility rate in female due to hormonal imbalance, and lifestyle changes are the factors boost in the region. Moreover, Asia Pacific garnered significant share due to rise in female adult population, rise in female genital mutilation, and adoption of newer drugs in the region are the factors expected to upsurge the revenue of market in the region.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2025-2031 |
|
Market Size in 2023 |
US$ 3.48 billion |
|
Market Size in 2030 |
US$ 5.35 billion |
|
Market CAGR |
6.3% |
|
By Drug Type |
|
|
By Route Administration |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
The global female fertility drugs market size was valued at US$ 3.48 billion in 2023 and is projected to grow at a CAGR of 6.3% from 2024 to 2030.
The market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
The market key players are Sanofi S.A. (France), Merck KGaA (Germany), Novartis AG (Switzerland), Ferring B.V. (Switzerland), Berlex Laboratories Inc. (U.S.), Eli Lilly and Co. (U.S.), Serono Inc. (U.S.), Novogyne Pharmaceuticals (U.S.), Pfizer, Inc. (U.S.)
| 1. Executive Summary |
| 2. Global Female Fertility Drugs Market Introduction |
| 2.1.Global Female Fertility Drugs Market - Taxonomy |
| 2.2.Global Female Fertility Drugs Market - Definitions |
| 2.2.1.Drug Type |
| 2.2.2.Route Administration |
| 2.2.3.Distribution Channel |
| 2.2.4.Region |
| 3. Global Female Fertility Drugs Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Female Fertility Drugs Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
| 4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Female Fertility Drugs Market By Drug Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 5.1. Gonadotrophins |
| 5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Aromatase Inhibitors |
| 5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Selective Estrogen Receptor Modulators |
| 5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Follicle Stimulating Hormones |
| 5.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Dopamine Agonists |
| 5.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Metformin Hydrochloride |
| 5.6.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Others |
| 5.7.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 6. Global Female Fertility Drugs Market By Route Administration, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 6.1. Oral |
| 6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Parenteral |
| 6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7. Global Female Fertility Drugs Market By Distribution Channel, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 7.1. Hospital pharmacies |
| 7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail pharmacies |
| 7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Online pharmacies |
| 7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8. Global Female Fertility Drugs Market By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9. North America Female Fertility Drugs Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 9.1. Drug Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Gonadotrophins |
| 9.1.2.Aromatase Inhibitors |
| 9.1.3.Selective Estrogen Receptor Modulators |
| 9.1.4.Follicle Stimulating Hormones |
| 9.1.5.Dopamine Agonists |
| 9.1.6.Metformin Hydrochloride |
| 9.1.7.Others |
| 9.2. Route Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Oral |
| 9.2.2.Parenteral |
| 9.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospital pharmacies |
| 9.3.2.Retail pharmacies |
| 9.3.3.Online pharmacies |
| 9.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10. Europe Female Fertility Drugs Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 10.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Gonadotrophins |
| 10.1.2.Aromatase Inhibitors |
| 10.1.3.Selective Estrogen Receptor Modulators |
| 10.1.4.Follicle Stimulating Hormones |
| 10.1.5.Dopamine Agonists |
| 10.1.6.Metformin Hydrochloride |
| 10.1.7.Others |
| 10.2. Route Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Oral |
| 10.2.2.Parenteral |
| 10.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospital pharmacies |
| 10.3.2.Retail pharmacies |
| 10.3.3.Online pharmacies |
| 10.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 11. Asia Pacific (APAC) Female Fertility Drugs Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 11.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Gonadotrophins |
| 11.1.2.Aromatase Inhibitors |
| 11.1.3.Selective Estrogen Receptor Modulators |
| 11.1.4.Follicle Stimulating Hormones |
| 11.1.5.Dopamine Agonists |
| 11.1.6.Metformin Hydrochloride |
| 11.1.7.Others |
| 11.2. Route Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Oral |
| 11.2.2.Parenteral |
| 11.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospital pharmacies |
| 11.3.2.Retail pharmacies |
| 11.3.3.Online pharmacies |
| 11.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12. Middle East and Africa (MEA) Female Fertility Drugs Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 12.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Gonadotrophins |
| 12.1.2.Aromatase Inhibitors |
| 12.1.3.Selective Estrogen Receptor Modulators |
| 12.1.4.Follicle Stimulating Hormones |
| 12.1.5.Dopamine Agonists |
| 12.1.6.Metformin Hydrochloride |
| 12.1.7.Others |
| 12.2. Route Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Oral |
| 12.2.2.Parenteral |
| 12.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospital pharmacies |
| 12.3.2.Retail pharmacies |
| 12.3.3.Online pharmacies |
| 12.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13. Latin America Female Fertility Drugs Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 13.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Gonadotrophins |
| 13.1.2.Aromatase Inhibitors |
| 13.1.3.Selective Estrogen Receptor Modulators |
| 13.1.4.Follicle Stimulating Hormones |
| 13.1.5.Dopamine Agonists |
| 13.1.6.Metformin Hydrochloride |
| 13.1.7.Others |
| 13.2. Route Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Oral |
| 13.2.2.Parenteral |
| 13.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospital pharmacies |
| 13.3.2.Retail pharmacies |
| 13.3.3.Online pharmacies |
| 13.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Sanofi S.A. (France) |
| 14.2.2.Merck KGaA (Germany) |
| 14.2.3.Novartis AG (Switzerland) |
| 14.2.4.Ferring B.V. (Switzerland) |
| 14.2.5.Berlex Laboratories Inc. (U.S.) |
| 14.2.6.Eli Lilly and Co. (U.S.) |
| 14.2.7.Serono, Inc. (U.S.) |
| 14.2.8.Novogyne Pharmaceuticals (U.S.) |
| 14.2.9.Pfizer, Inc. (U.S.) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Sample
